Page 1

UK NORDIC BALTIC SUMMIT: 19-20 JANUARY 2011 ESTONIA

DENMARK

ICELAND

FINLAND

LATVIA

UNITED KINGDOM

NORWAY

LITHUANIA

SWEDEN


THEME:

[Green Economy/Sustainable Business]

TITLE OF PRESENTATION: Synergy of IT and Life Sciences in testing for new medical treatments and control of chemical environment

Synopsis:

As foreseen in regulations including REACH, more attention will be paid to identification of the properties of chemical substances and their influence on human health and the environment. Savings in time, money and animal tests are possible via computational prediction of chemical compounds and materials with predetermined properties. Example of Molcode, Ltd.

Presenter: Mati Karelson, Member of Estonian Academy of Sciences, Research and Science Advisor to the Estonian Prime Minister

Short Biography:

Professor at the University of Tartu and Tallinn University of Technology, one of the most cited Estonian scientists, he has published over 190 scientific articles, monographs and monographic reviews, several patent inventions, member of Estonian R&D Council. His work is currently used in several innovative biotech and information technology companies.


CHALLENGES ENVIRONMENTAL CONTROL AND HEALTH

It has been estimated that the REACH legislation alone could lead to a demand for up to 45 million laboratory animals in next 15 years

high cost time-consuming relevance to human organism ethical problems

ALTERNATIVES ?


MOLCODE, Ltd. Computational prediction of chemical compounds and materials with predetermined properties (QSARSOFT WizardŠ) A combination of information technology with advancements in life sciences

ENGINES (IT)

DATA (LS)


ALTERNATIVES TO ANIMAL TESTS Molcode provides alternative computational data for most properties required by REACH legislation, allowing huge savings in terms of time, money and lives (the first in the world market). Computational models validated and approved by EU Joint Research Centre.


CHALLENGES LIFE QUALITY OF AGING POPULATION Almost 1 in 5 adults in Europe suffers from long-term pain – at least 75 million people

20 1

0

Expenditures ($billion)

Source: Pain in Europe Study, 2003

The treatment of neurodegenerative diseases costs annually European health services approximately €72 billion. Source: IP/10/431, Brussels, 15th April 2010

Existing treatments are limited, and mainly treat the symptoms, rather than addressing the cause.

Sources: Tufts CSDD 2006 Outlook Report, PhRMA, ww.fda.gov

SOLUTIONS ?


NEW THERAPIES FOR NEURODEGENERATIVE DISEASES MIMETICS OF NEUROTROPHIC FACTORS In vivo proof-of-principle of GDNF mimetics against Parkinson’s disease (6-OHDA rat model)

Drug-4 and Drug-16 are acting as efficiently or better than GDNF itself

Synergy of IT and Life Sciences in testing  

Mati Karelson, Member of Estonian Academy of Sciences, Research and Science Advisor to the Estonian Prime Minister.

Synergy of IT and Life Sciences in testing  

Mati Karelson, Member of Estonian Academy of Sciences, Research and Science Advisor to the Estonian Prime Minister.

Advertisement